JAZZ - FDA Report On Its 50 Years In Cannabis Research Signals A Boost In Medical Marijuana Prospects | Benzinga
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled "FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development”, the authors summarize a recent FDA report published in Open Exploration. In short, the FDA researchers and article authors, Cassandra Taylor and Schuyler Pruyn present a breakdown of cannabis and cannabis-derived products (CCDP) applications that the agency has received over.
The document comes some two months after Health and Human Services (HHS) Secretary Xavier Becerra confirmed his agency has recommended cannabis should be rescheduled.
Per the report, since the early 1970s, the agency obtained more than 800 investigational new drug drug applications (INDs), and pre-investigational new drug applications (pre-INDs) related to CCDP.
"Over the last 10 years, there has been increased interest in studying CCDPs as medical treatment options,” the article reads. "We have received double the number of IND and pre-IND applications during this time.”
The authors highlight that the article also helps the agency bust the myths around the types of CCDP research the FDA ...